2023, Volume 25, Issue 5
Strategic Study of CAE >> 2023, Volume 25, Issue 5 doi: 10.15302/J-SSCAE-2023.05.006
Optimal Constructing Measures of Novel Research and Development Institutions in Life Sciences and Medicine in China
1. School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100730, China;
2. China National Health Development Research Center, Beijing 100044, China;
3. Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences & School of Basic Medicine of the Peking Union Medical College,Beijing 100005, China;
4. State Key Laboratory of Common Mechanism Research for Major Diseases, Beijing 100005, China;
5. Haihe Laboratory of Cell Ecosystem, Tianjin 300462, China;
6. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China;
7. National Key Laboratory of Blood Science, Tianjin 300020, China;
8. National Clinical Research Center for Blood Diseases, Tianjin 300020, China;
9. Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;
10. Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China
Next Previous
Abstract
Novel research and development (R&D) institutions are an important organizational form of scientific and technological innovation in China. Novel R&D institutions in life sciences and medicine are oriented toward people’s life and health and play an important role in promoting the development of life sciences and medicine, forming multiple innovation subjects, and building an innovation ecology with active elements. However, their construction is still in an exploration stage, and it is urgent to optimize the construction strategy and form a stable and sustainable development capability. This study used the methods of policy research, on-site research, case study, and expert consultation to summarize the progress of policy promotion and exploration practices of novel R&D institutions in China, analyzed the construction modes and operation mechanisms of similar R&D institutions abroad, and presented challenges in the development of novel R&D institutions in the field of life sciences and medicine in China. On this basis, we proposed the following strategies for optimizing the construction of novel R&D institutions in life sciences and medicine in China: (1) building up a diversified and stable funding mechanism, (2) establishing a differentiated development path, (3) improving the recruiting and cultivating mechanism of outstanding professionals, (4) continuously innovating the organizational form of scientific research, (5) exploiting the advantages of the flexible mechanism for scientific achievement transformation, and (6) enhancing the academic influence of these institutions, thereby promoting the high-quality development of these institutions and the self-reliance and strength of China in science and technology.
Keywords
life science ; medicine ; novel R&D institutions ; construction strategy ; scientific and technological innovation
References
[ 1 ]
中华人民共和国科学技术部 . 关于促进新型研发机构发展的指导意见 [EBOL]. 2019-09-12 [ 2023-07-07 ]. https: www.gov.cngongbaocontent2020content_5469722.htm?ivk_sa=1024320u .
Ministry of Science and Technology of the People´s Republic of China . Guidance on promoting the development of new RD institutions [EBOL]. 2019-09-12 [ 2023-07-07 ]. https: www.gov.cngongbaocontent2020content_5469722.htm?ivk_sa=1024320u .
link1
[ 2 ]
徐艳 , 王丽萍 . 长三角新型研发机构发展现状及建议 [J]. 华东科技 , 2022 8 : 41 – 45 .
Xu Y , Wang L P . Development status and suggestions of new RD institutions in Yangtze River Delta [J]. East China Science and Technology , 2022 8 : 41 – 45 .
[ 3 ]
科技部火炬中心 . 2022年新型研发机构发展报告 [M]. 北京 : 科学技术文献出版社 , 2023 .
Torch Center of the Ministry of Science and Technology of the People´s Republic of China . New RD institution development report 2022 [M]. Beijing : Scientific and Technical Documentation Press , 2023 .
[ 4 ]
湖北省科学技术厅 . 湖北省新型研发机构达452家居全国前列 [EBOL]. 2023-06-15 [ 2023-07-10 ]. https: www.most.gov.cndfkjhubzxdt202306t20230615_186611.html .
Department of Science and Technology of Hubei Province . The number of new research and development institutions in Hubei Province has reached 452 in the forefront of China [EBOL]. 2023-06-15 [ 2023-07-10 ]. https: www.most.gov.cndfkjhubzxdt202306t20230615_186611.html .
link1
[ 5 ]
中国生物技术发展中心 . 2022中国生物医药产业园区竞争力评价及分析报告 [R]. 北京 : 中国生物技术发展中心 , 2023 .
China National Center for Biotechnology Development . Report on competitiveness evaluation and analysis of China biomedical industrial parks in 2022 was officially released [R]. Beijing : China National Center for Biotechnology Development , 2023 .
[ 6 ]
韩凤芹 , 陈亚平 . 财政支持新型研发机构的探讨——困境、借鉴与改革路径 [J]. 中国高校科技 , 2023 4 : 33 – 40 .
Han F Q , Chen Y P . Discussion on financial support for new RD institutions: dilemma, reference and reform path [J]. China University Science Technology , 2023 4 : 33 – 40 .
[ 7 ]
杨凌春 , 张琰 . 从美国Broad Institute看"协同创新" [J]. 研究与发展管理 , 2014 , 26 6 : 122 – 128 .
Yang L C , Zhang Y . A study of collaborative innovation from Broad Institute [J]. RD Management , 2014 , 26 6 : 122 – 128 .
[ 8 ] Institute Broad. David R Liu, Ph.D. [EB/OL]. [2023-07-20]. https: //www.broadinstitute.org/bios/david-liu. link1
[ 9 ] SALK. Awards and accolades [EB/OL]. [2023-07-20]. https: //www.salk.edu/about/awards-and-accolades/. link1
[10] Institute McGovern. McGovern institute director receives highest honor from the society for neuroscience [EB/OL]. [2023-07-20]. https: //mcgovern.mit.edu/2021/11/08/mcgovern-institute-director-receives-highest-honor-from-the-society-for-neuroscience/. link1
[11]
陈少毅 , 吴红斌 . 创新驱动战略下新型研发机构发展的问题及对策 [J]. 宏观经济管理 , 2018 6 : 43 – 49 .
Chen S Y , Wu H B . Problems and countermeasures of the development of new RD institutions under the innovation-driven strategy [J]. Macroeconomic Management , 2018 6 : 43 – 49 .
京公网安备 11010502051620号
